Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer.

Blake, Devon R; Vaseva, Angelina V; Hodge, Richard G; Kline, McKenzie P; Gilbert, Thomas S K; Tyagi, Vikas; Huang, Daowei; Whiten, Gabrielle C; Larson, Jacob E; Wang, Xiaodong; Pearce, Kenneth H; Herring, Laura E; Graves, Lee M; Frye, Stephen V; Emanuele, Michael J; Cox, Adrienne D; Der, Channing J

Blake, Devon R; Vaseva, Angelina V; Hodge, Richard G; Kline, McKenzie P; Gilbert, Thomas S K; Tyagi, Vikas; Huang, Daowei; Whiten, Gabrielle C; Larson, Jacob E; Wang, Xiaodong; Pearce, Kenneth H; Herring, Laura E; Graves, Lee M; Frye, Stephen V; Emanuele, Michael J; Cox, Adrienne D; Der, Channing J.

Affiliation

Blake DR; Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Vaseva AV; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Hodge RG; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Kline MP; Department of Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Gilbert TSK; Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Tyagi V; UNC Michael Hooker Proteomics Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Huang D; Center for Integrative Chemical Biology and Drug Discovery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Whiten GC; Center for Integrative Chemical Biology and Drug Discovery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Larson JE; Center for Integrative Chemical Biology and Drug Discovery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Wang X; Center for Integrative Chemical Biology and Drug Discovery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Pearce KH; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Herring LE; Center for Integrative Chemical Biology and Drug Discovery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Graves LM; Center for Integrative Chemical Biology and Drug Discovery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Frye SV; Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Emanuele MJ; UNC Michael Hooker Proteomics Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Cox AD; Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Der CJ; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

Sci Signal ; 12(590)2019 07 16.

Article de En | MEDLINE | ID: mdl-31311847

Sujet(s)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs du pancréas / Tests de criblage d'agents antitumoraux / Protéines proto-oncogènes p21(ras) / Protéines proto-oncogènes c-myc / Kinase-9 cycline-dépendante / Inhibiteurs de protéines kinases Type d'étude: Diagnostic_studies Limites: Humans Langue: En Journal: Sci Signal Sujet du journal: CIENCIA / FISIOLOGIA Année: 2019 Type de document: Article Pays d'affiliation: États-Unis d'Amérique Pays de publication: États-Unis d'Amérique

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google